BioNexus Gene Lab Corp. Proceeds from Dividends Received
BioNexus Gene Lab Corp. (BGLC) reported Proceeds from Dividends Received of $22.11 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDividendsReceived · last filed 2026-04-14
- BioNexus Gene Lab Corp. proceeds from dividends received for the quarter ending 2025-12-31 was $360.00, a 95.75% decline year-over-year.
- BioNexus Gene Lab Corp. proceeds from dividends received for the quarter ending 2025-09-30 was $4.19K, a 89.20% decline year-over-year.
- BioNexus Gene Lab Corp. proceeds from dividends received for the quarter ending 2024-12-31 was $8.48K.
- BioNexus Gene Lab Corp. proceeds from dividends received for the quarter ending 2024-09-30 was $38.83K.
- BioNexus Gene Lab Corp. proceeds from dividends received for fiscal 2025 was $22.11K, a 67.54% decline from fiscal 2024.
- BioNexus Gene Lab Corp. proceeds from dividends received for fiscal 2024 was $68.13K.
| Period end | Proceeds from Dividends Received 3 month | Proceeds from Dividends Received 6 month | Proceeds from Dividends Received 9 month | Proceeds from Dividends Received 12 month |
|---|---|---|---|---|
| 2025-12-31 | $360.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $4.55K derived: sum of 2 quarters · filed 2026-04-14 | $22.11K 10-K · filed 2026-04-14 | |
| 2025-09-30 | $4.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $21.75K 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $17.56K 10-Q · filed 2025-08-18 | |||
| 2024-12-31 | $8.48K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $47.30K derived: sum of 2 quarters · filed 2026-04-14 | $68.13K 10-K · filed 2026-04-14 | |
| 2024-09-30 | $38.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $59.65K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $20.83K 10-Q · filed 2025-08-18 | |||
| 2022-06-30 | $19.32K 10-Q · filed 2022-08-15 | |||
| 2021-06-30 | $11.06K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |